Home › NCT06020508

Lumoptik BRIGHTPOINT Reflectometer Device for Lumbar Epidural Placement

Pilot Study for Human Clinical Trial to Evaluate the BRIGHTPOINT Reflectometer Device as Secondary Confirmation to Loss of Resistance in Lumbar Epidural Placement

Who can join

Ages 18 to 99 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Any patient undergoing a lumbar neuraxial procedure requiring epidural needle
* Age 18-99

Exclusion Criteria:

* Previous lumbar spine surgery
* Any known spinal abnormality that would interfere with successfully advancing a needle into the epidural space
* Any patient requiring epidural needle longer than 4 inches
* Any contraindication to neuraxial anesthesia
* Tattoo at the site of epidural insertion

About the study

The goal of this clinical trial is to test the BrightPoint Epidural device as the first system to use multispectral reflectometry to find the epidural space in lumbar neuraxial procedures requiring epidural needle. The main questions it aims to answer are:

1. Is the device a qualitatively effective secondary confirmation of Loss of Resistance? 2. Is the device a qualitatively effective training tool for educating trainees in how to perform lumbar epidurals?

Participants will undergo a neuraxial procedure in which the attending anesthesiologist will use the BrightPoint epidural device to form an opinion on its effectiveness in confirming epidural space access.

What is being tested

• Group 1 - Lumoptik BrightPoint Epidural Device (device)

Sponsor: Hospital for Special Surgery, New York · Participants: 36 · Started: Sep 12, 2023

Contact the study team

• Pa Thor, PhD · Phone: 646-797-8535
• Maya Tailor · Phone: 646-714-6828

Official record on ClinicalTrials.gov — NCT06020508

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.